Kamada Announces $11.4 Million International VARIZIG® Procurement Agreement
REHOVOT, Israel and HOBOKEN, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today that it has secured an $11.4 million agreement to supply VARIZIG to an undisclosed international organization, operating principally in Latin America.
- REHOVOT, Israel and HOBOKEN, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today that it has secured an $11.4 million agreement to supply VARIZIG to an undisclosed international organization, operating principally in Latin America.
- The supply of the product is expected to occur from the fourth quarter of 2022 through the first half of 2023.
- VARIZIG is intended to reduce the severity of chickenpox infections in these patients.
- VARIZIG is manufactured by Emergent BioSolutions (NYSE: EBS) at their facility in Winnipeg, MB, Canada, under a contract development and manufacturing (CDMO) service agreement.